SCHEMBL2230447

SCHEMBL2230447

COc1ccc2cc(OCC3CCNC3)ccc2c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 6/20 0.76
SLC6A4 P31645 6/20 0.76
SLC6A3 Q01959 3/20 0.76
KCNH2 Q12809 4/20 0.62
HTR3A P46098 2/20 0.62
TDP1 Q9NUW8 1/20 0.61
PRKCZ Q05513 2/20 0.52
MAP2K1 Q02750 1/20 0.51
EED O75530 1/20 0.46
KDM1A O60341 5/20 0.44
RCOR1 Q9UKL0 1/20 0.43
DYRK3 O43781 1/20 0.43
CLK1 P49759 1/20 0.43
CLK2 P49760 1/20 0.43
CLK3 P49761 1/20 0.43
DYRK1A Q13627 1/20 0.43
DYRK2 Q92630 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
DYRK4 Q9NR20 1/20 0.43
DYRK1B Q9Y463 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1526884 0.88 SLC6A2 (0.76) SLC6A2SLC6A4SLC6A3KCNH2HTR3A
SCHEMBL2227826 0.87 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3KCNH2HTR3A
SCHEMBL2227832 0.87 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3KCNH2HTR3A
SCHEMBL2228515 0.87 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3KCNH2HTR3A
SCHEMBL2170234 0.83 SLC6A2 (0.54) SLC6A2SLC6A4SLC6A3KCNH2HTR3A
SCHEMBL2245058 0.83 SLC6A2 (0.54) SLC6A2SLC6A4SLC6A3KCNH2HTR3A
SCHEMBL13107014 0.80 EED (0.67) SLC6A2SLC6A4SLC6A3TDP1MAP2K1
SCHEMBL2230001 0.80 SLC6A2 (0.71) SLC6A2SLC6A4SLC6A3KCNH2HTR3A
SCHEMBL791643 0.79 TDP1 (0.69) SLC6A2SLC6A4SLC6A3KCNH2HTR3A
SCHEMBL3443378 0.79 TDP1 (0.65) SLC6A2SLC6A4SLC6A3TDP1MAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000010-B2 Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application SANOFI (FR) 2015-04-07 US disclosed
EP-2526100-B1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2013-12-04 EP disclosed
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2012-11-22 US disclosed
WO-2011089550-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2011-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION PRMT9, PRMT8, CBR1 SLC6A2 2876/4885SLC6A4 3841/4885SLC6A3 2474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.